
Marzena Olesinska

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8630600/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Annals of the Rheumatic Diseases, 2017, 76, 1955-1964.	0.9	754
2	2017 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies and Their Major Subgroups. Arthritis and Rheumatology, 2017, 69, 2271-2282.	5.6	391
3	Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respiratory Medicine,the, 2020, 8, 963-974.	10.7	348
4	A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS). Annals of the Rheumatic Diseases, 2017, 76, 554-561.	0.9	268
5	Current causes of death in systemic lupus erythematosus in Europe, 2000—2004: relation to disease activity and damage accrual. Lupus, 2007, 16, 309-317.	1.6	189
6	Disease activity and damage accrual during the early disease course in a multinational inception cohort of patients with systemic lupus erythematosus. Lupus, 2010, 19, 949-956.	1.6	134
7	Capillaroscopy – a role in modern rheumatology. Reumatologia, 2016, 54, 67-72.	1.1	71
8	Quality of life in systemic lupus erythematosus and its measurement. Reumatologia, 2018, 56, 45-54.	1.1	67
9	Antimalarials – are they effective and safe in rheumatic diseases?. Reumatologia, 2018, 56, 164-173.	1.1	65
10	Anti-influenza vaccination in systemic lupus erythematosus patients: an analysis of specific humoral response and vaccination safety. Clinical Rheumatology, 2010, 29, 605-613.	2.2	63
11	2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Adult Dermatomyositis and Polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Arthritis and Rheumatology, 2017, 69, 898-910.	5.6	52
12	Clinical features and prognosis of patients with idiopathic inflammatory myopathies and anti-Jo-1 antibodies. Autoimmunity, 2006, 39, 243-247.	2.6	51
13	Current Understanding of an Emerging Role of HLA-DRB1 Gene in Rheumatoid Arthritis–From Research to Clinical Practice. Cells, 2020, 9, 1127.	4.1	51
14	Vitamin D receptor gene Bsml, Fokl, Apal and Taql polymorphisms and the risk of systemic lupus erythematosus. Molecular Biology Reports, 2013, 40, 803-810.	2.3	49
15	Polyautoimmunity in rheumatological conditions. International Journal of Rheumatic Diseases, 2019, 22, 386-391.	1.9	32
16	Relationship between VEGF Gene Polymorphisms and Serum VEGF Protein Levels in Patients with Rheumatoid Arthritis. PLoS ONE, 2016, 11, e0160769.	2.5	32
17	Association of Single Nucleotide Polymorphisms in the <i><scp>IL</scp>27</i> Gene with Rheumatoid Arthritis. Scandinavian Journal of Immunology, 2014, 80, 298-305.	2.7	30
18	Rivaroxaban – a safe therapeutic option in patients with antiphospholipid syndrome? Our experience in 23 cases. Reumatologia, 2016, 3, 146-149.	1.1	29

#	Article	IF	CITATIONS
19	Factors associated with quality of life in systemic sclerosis: a cross-sectional study. Quality of Life Research, 2019, 28, 3347-3354.	3.1	29
20	Serum concentration of interleukin 15, interleukin 2 receptor and TNF receptor in patients with polymyositis and dermatomyositis: correlation to disease activity. Rheumatology International, 2012, 32, 639-643.	3.0	28
21	Association of HLAâ€DRB1 alleles with susceptibility to mixed connective tissue disease in Polish patients. Hla, 2016, 87, 13-18.	0.6	24
22	Contribution of STAT4 gene single-nucleotide polymorphism to systemic lupus erythematosus in the Polish population. Molecular Biology Reports, 2012, 39, 8861-8866.	2.3	23
23	Genetic Polymorphisms of <i>Foxp3</i> in Patients with Rheumatoid Arthritis. Journal of Rheumatology, 2015, 42, 170-180.	2.0	22
24	Genetic Variants in <i><scp>IL</scp>â€12B</i> and <i><scp>IL</scp>â€27</i> in the Polish Patients with Systemic Lupus Erythematosus. Scandinavian Journal of Immunology, 2016, 84, 49-60.	2.7	21
25	Tofacitinib in the treatment of patients with rheumatoid arthritis: position statement of experts of the Polish Society for Rheumatology. Reumatologia, 2018, 56, 203-211.	1.1	21
26	The Phenotype and Secretory Activity of Adipose-Derived Mesenchymal Stem Cells (ASCs) of Patients with Rheumatic Diseases. Cells, 2019, 8, 1659.	4.1	21
27	Contribution of toll-like receptor 9 gene single-nucleotide polymorphism to systemic lupus erythematosus. Rheumatology International, 2013, 33, 1121-1125.	3.0	20
28	Neutrophil extracellular traps generation and degradation in patients with granulomatosis with polyangiitis and systemic lupus erythematosus. Autoimmunity, 2019, 52, 126-135.	2.6	20
29	Differential association of juvenile and adult systemic lupus erythematosus with genetic variants of oestrogen receptors alpha and beta. Lupus, 2011, 20, 85-89.	1.6	18
30	Neuropsychological assessment in mixed connective tissue disease: comparison with systemic lupus erythematosus. Lupus, 2012, 21, 927-933.	1.6	18
31	ITGAM Arg77His Is Associated with Disease Susceptibility, Arthritis, and Renal Symptoms in Systemic Lupus Erythematosus Patients from a Sample of the Polish Population. DNA and Cell Biology, 2011, 30, 33-38.	1.9	17
32	Monocyte Chemoattractant Protein-1 <mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mrow><mml:mo>â^²</mml:mo></mml:mrow>A/G Single Nucleotide Polymorphism Might Be Associated with Renal Disease and Thrombocytopenia of SLE. Journal of Biomedicine and Biotechnology, 2010, 2010, 1-6.</mml:math 	ml:math>2	2518 15
33	Systemic lupus erythematosus: the influence of disease-related and classical risk factors on intima media thickness and prevalence of atherosclerotic plaques - a preliminary report. Beneficial effect of immunosuppressive treatment on carotid intima media thickness. Acta Cardiologica, 2015, 70, 169-175.	0.9	15
34	<scp>IL</scp> â€12B Gene Polymorphisms and <scp>IL</scp> â€12 p70 Serum Levels Among Patients with Rheumatoid Arthritis. Scandinavian Journal of Immunology, 2017, 85, 147-154.	2.7	15
35	IL-35, TNF-α, BAFF, and VEGF serum levels in patients with different rheumatic diseases. Reumatologia, 2019, 57, 145-150.	1.1	14
36	Global miRNA and mRNA expression profiles identify miRNAâ€26aâ€2â€3pâ€dependent repression of IFN signature in systemic sclerosis human monocytes. European Journal of Immunology, 2020, 50, 1057-1066.	2.9	14

#	Article	IF	CITATIONS
37	Single nucleotide polymorphism of <i>CD40</i> region and the risk of systemic lupus erythematosus. Lupus, 2013, 22, 233-237.	1.6	13
38	KDR (VEGFR2) Genetic Variants and Serum Levels in Patients with Rheumatoid Arthritis. Biomolecules, 2019, 9, 355.	4.0	13
39	JHDM1D and HDAC1–3 mRNA expression levels in peripheral blood mononuclear cells of patients with systemic lupus erythematosus. Zeitschrift Fur Rheumatologie, 2015, 74, 902-910.	1.0	12
40	Impact of the <i>IL-17F, IL-23</i> and <i>IL-23R</i> on susceptibility and phenotype of systemic lupus erythematosus. Autoimmunity, 2016, 49, 373-382.	2.6	12
41	Subgroups of Sjögren's syndrome patients categorised by serological profiles: clinical and immunological characteristics. Reumatologia, 2018, 56, 346-353.	1.1	12
42	Observational study of inflammatory arthritis treatment by etanercept originator switched to an etanercept biosimilar. Reumatologia, 2019, 57, 257-263.	1.1	12
43	Recognizing systemic sclerosis: comparative analysis of various sets of classification criteria. Reumatologia, 2016, 54, 296-305.	1.1	11
44	Epigenetics: The Future Direction in Systemic Sclerosis. Scandinavian Journal of Immunology, 2017, 86, 427-435.	2.7	11
45	Prevalence of the NKG2D Thr72Ala polymorphism in patients with systemic lupus erythematosus. Molecular Biology Reports, 2012, 39, 1343-1347.	2.3	10
46	Modulation of T-Cell Activation Markers Expression by the Adipose Tissue–Derived Mesenchymal Stem Cells of Patients with Rheumatic Diseases. Cell Transplantation, 2020, 29, 096368972094568.	2.5	10
47	TNF-308G/A polymorphism and risk of systemic lupus erythematosus in the Polish population. Modern Rheumatology, 2015, 25, 719-723.	1.8	9
48	Treatment of rheumatic diseases and hepatitis B virus coinfection. Rheumatology International, 2015, 35, 385-392.	3.0	9
49	Optimism, pain coping strategies and pain intensity among women with rheumatoid arthritis. Reumatologia, 2014, 52, 166-171.	1.1	8
50	Association of the Smad3 and NFATc2 gene polymorphisms and their serum levels with susceptibility to rheumatoid arthritis in Polish cohorts. Clinical and Experimental Immunology, 2015, 179, 444-453.	2.6	8
51	IL-10, IL-12B and IL-17 gene polymorphisms in patients with mixed connective tissue disease. Modern Rheumatology, 2015, 25, 487-489.	1.8	8
52	Assessment of education requirements for patients with rheumatoid arthritis, based on the Polish version of the Educational Needs Assessment Tool (Pol-ENAT), in the light of some health problems – A cross-sectional study. Annals of Agricultural and Environmental Medicine, 2016, 23, 361-367.	1.0	8
53	Impact and Possible Mechanism(s) of Adipose Tissue-Derived Mesenchymal Stem Cells on T-Cell Proliferation in Patients With Rheumatic Disease. Frontiers in Physiology, 2021, 12, 749481.	2.8	8
54	Target Therapies in Systemic Lupus Erythematosus: Current State of the Art. Mini-Reviews in Medicinal Chemistry, 2010, 10, 956-965.	2.4	7

#	Article	IF	CITATIONS
55	B-cell targeted therapy in systemic lupus erythematosus: potential of rituximab. Biologics: Targets and Therapy, 2012, 6, 347.	3.2	7
56	Genetic variants of <i>DNMT3A</i> and systemic lupus erythematosus susceptibility. Modern Rheumatology, 2015, 25, 96-99.	1.8	7
57	HIF-1A gene polymorphisms and its protein level in patients with rheumatoid arthritis: a case–control study. Inflammation Research, 2018, 67, 423-433.	4.0	7
58	Satisfaction and discontent of Polish patients with biological therapy of rheumatic diseases: results of a multi-center questionnaire study. Reumatologia, 2018, 56, 140-148.	1.1	7
59	The Role of MECP2 and CCR5 Polymorphisms on the Development and Course of Systemic Lupus Erythematosus. Biomolecules, 2020, 10, 494.	4.0	7
60	The <i>FCRL3</i> â^`169T>C polymorphism might be associated with some autoantibody presence in patients with SLE in a Polish population. Modern Rheumatology, 2014, 24, 296-299.	1.8	6
61	Immunity and early atherosclerosis in the course of systemic lupus erythematosus, mixed connective tissue disease and antiphospholipid syndrome. Reumatologia, 2016, 54, 187-195.	1.1	6
62	Lack of association between rheumatoid arthritis and genetic variants rs10889677, rs11209026 and rs2201841 of IL-23R gene. Medicina ClÃnica, 2018, 151, 191-195.	0.6	6
63	FLT-1 gene polymorphisms and protein expression profile in rheumatoid arthritis. PLoS ONE, 2017, 12, e0172018.	2.5	6
64	Clinical manifestation of systemic lupus erythematosus in patients with antiribosomal P protein antibodies. Polish Archives of Internal Medicine, 2010, 120, 76-81.	0.4	6
65	Discrepancies in assessment of patients with rheumatoid arthritis and secondary Sjögren's syndrome by DAS28-ESR and DAS28-CRP. Central-European Journal of Immunology, 2016, 2, 188-194.	1.2	5
66	Levels of Antibodies against Human Heat Shock Protein (HSP) 60 in Patients with Glaucoma in Poland. Medical Science Monitor, 2015, 21, 828-832.	1.1	5
67	Evaluation of systemic lupus erythematosus activity during pregnancy. Polish Archives of Internal Medicine, 2007, 117, 312-316.	0.4	4
68	Esophageal transit scintigraphy in systemic sclerosis. Reumatologia, 2016, 54, 251-255.	1.1	3
69	RORC2 Genetic Variants and Serum Levels in Patients with Rheumatoid Arthritis. International Journal of Molecular Sciences, 2016, 17, 488.	4.1	3
70	Differential diagnosis of idiopathic inflammatory myopathies in adults – the first step when approaching a patient with muscle weakness. Reumatologia, 2018, 56, 307-315.	1.1	3
71	Association study between immune-related miRNAs and mixed connective tissue disease. Arthritis Research and Therapy, 2021, 23, 19.	3.5	3
72	Impact of Adipose-Derived Mesenchymal Stem Cells (ASCs) of Rheumatic Disease Patients on T Helper Cell Differentiation. International Journal of Molecular Sciences, 2022, 23, 5317.	4.1	3

#	Article	IF	CITATIONS
73	Recommendations for diagnosis and treatment Selected principles of proper education of women with rheumatic diseases in respect of pregnancy planning. Reumatologia, 2014, 1, 49-56.	1.1	2
74	Fertility, pregnancy planning, and pharmacotherapy during the pregnancy, postpartum and breastfeeding period in patients with rheumatoid arthritis and other inflammatory arthropathies. Reumatologia, 2014, 52, 7-21.	1.1	2
75	Takayasu arteritis: is disease activity assessment possible?. Reumatologia, 2013, 2, 144-150.	1.1	1
76	Interleukin 6 blockage-induced neutropenia in a patient with rheumatoid arthritis and resolved hepatitis B. Reumatologia, 2015, 6, 337-340.	1.1	1
77	SAT0195â€Early Nailfold Capillaroscopic Pattern Predominates in Patients with Mixed Connective Tissue Disease. Annals of the Rheumatic Diseases, 2016, 75, 738.3-738.	0.9	1
78	Lack of significant association between selected STAT3 polymorphisms and rheumatoid arthritis in the Polish population. Reumatologia, 2018, 56, 73-79.	1.1	1
79	Recommendations for diagnosis and treatment Recommendations for obstetric management and principles of cooperation between rheumatologists and obstetricians in systemic connective tissue disease patients. Reumatologia, 2014, 1, 38-48.	1.1	0
80	Recommendations for diagnosis and treatment Fertility, pregnancy planning, and treatment during the pregnancy, postpartum and breastfeeding period in patients with antiphospholipid syndrome. Reumatologia, 2014, 1, 30-37.	1.1	0
81	Recommendations for diagnosis and treatment Fertility, pregnancy and breastfeeding in systemic lupus erythematosus patients. Reumatologia, 2014, 1, 22-29.	1.1	0
82	AB0586â€Predictors of Interstitial Lung Disease in 79 Patients with Mixed Connective Tissue Disease. Annals of the Rheumatic Diseases, 2016, 75, 1105.1-1105.	0.9	0
83	AB0275â€Differences in The Clinical Evaluation of Joints in Patients with Rheumatoid Arthritis and Secondary Sjögren Syndrome. Annals of the Rheumatic Diseases, 2016, 75, 993.3-994.	0.9	0
84	AB0002â€Genetic Variants in IL-17F, IL-23 and IL-23R in The Patients with Systemic Lupus Erythematosus. Annals of the Rheumatic Diseases, 2016, 75, 897.2-897.	0.9	0
85	AB0001â€Genetic Variants in IL-12B and IL-27 in The Patients with Systemic Lupus Erythematosus. Annals of the Rheumatic Diseases, 2016, 75, 897.1-897.	0.9	0
86	THU0012â€HLA-DBR1 alleles profile in patients with rheumatoid arthritis: relation to disease susceptibility and severity. , 2017, , .		0
87	03.15â€Identification of novel micrornas in monocytes from rheumatoid arthritis and systemic sclerosis patients using next generation sequencing. , 2017, , .		0
88	AB1184â€Educational needs of patients with rheumatic diseases receiving biologics. , 2017, , .		0
89	Sarcoidosis: selected clinical cases. Polish Archives of Internal Medicine, 2009, 119, 514-517.	0.4	0
90	Polyautoimmunity: aÂsignificant issue inÂconnective tissue diseases. Polish Archives of Internal Medicine, 2016, 126, 837-838.	0.4	0

#	Article	IF	CITATIONS
91	TheÂinternal medicine in crisis: theÂanalysis of causes and proposed changes. Polish Archives of Internal Medicine, 2016, 126, 1068-1073.	0.4	0
92	AB0775â€Characteristics of patients with scleroderma (SSC) treated with various drugs in the clinical assessment and tgf Î' and il13 concentration in comparison to the healthy group. , 2018, , .		0
93	FRI0429â€Distinct clinical and immunological picture of mctd patients with skin involvement. , 2018, , .		0